Related Experiment Video
Updated: Oct 15, 2025

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
Published on: September 24, 2021
[Acute myocarditis in a young adult two days after Pfizer vaccination]
Sara Facetti1, Mario Giraldi1, Andrea Lorenzo Vecchi2
1U.O. Cardiologia, P.O. Saronno, ASST Valle Olona, Busto Arsizio (VA).
Abstract:
We report the case of a 20-year-old healthy male who developed acute myopericarditis 2 days after receiving the second dose of the mRNA Pfizer-BioNTech COVID-19 vaccine. The course of the disease was mild and the patient was discharged after a few days of hospitalization.Recently, several case reports involving myopericarditis in patients who received an mRNA vaccine against SARS-CoV-2 have been published and the U.S. Centers for Disease Control and Prevention and the European Medicines Agency pharmacovigilance risk assessment committee are currently investigating an overall increased number of cases. They are also assessing whether there is a higher incidence than expected in vaccinated young adults and teenagers, especially males. Although a clear causal link has not been proven at this time, physicians should be aware of such potential adverse event, taking into account the increasing number of young people that will receive mRNA vaccination over the next few months.
Insights
A young male developed mild acute myopericarditis after his second Pfizer-BioNTech COVID-19 vaccine dose. This rare adverse event is under investigation by health agencies for vaccinated young adults and males.
Area of Science:
- Cardiology
- Vaccinology
- Public Health
Background:
- The widespread rollout of mRNA COVID-19 vaccines has led to extensive monitoring for potential adverse events.
- Myopericarditis, inflammation of the heart muscle and outer lining, is a rare but serious condition.
- Recent reports suggest a possible association between mRNA COVID-19 vaccination and myopericarditis, particularly in younger demographics.
Observation:
- A case study details a 20-year-old healthy male who presented with acute myopericarditis two days post-second dose of the Pfizer-BioNTech mRNA COVID-19 vaccine.
- The patient experienced a mild clinical course and was discharged after a brief hospitalization.
Findings:
- While a definitive causal link is not yet established, this case adds to a growing number of reported myopericarditis cases following mRNA COVID-19 vaccination.
- Regulatory bodies like the CDC and EMA are actively investigating an increased incidence of myopericarditis in vaccinated young adults and adolescents, especially males.
Implications:
- Healthcare providers should maintain awareness of potential cardiac adverse events, including myopericarditis, following mRNA COVID-19 vaccination.
- This information is crucial for informed decision-making as vaccination campaigns expand to include younger populations.
- Further research is warranted to elucidate the incidence, risk factors, and underlying mechanisms of vaccine-associated myopericarditis.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Pericarditis I: Introduction
Myocarditis IV: Nursing Management
Endocarditis I: Introduction

